IP Library › Granted Patent US 8,044,181
Granted Patent B2
US 8,044,181 · App. 12/325,806 · Granted Oct 25, 2011

Antibodies to the PcrV antigen of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,044,181
App. No.
12/325,806
Granted
Oct 25, 2011
Kind
B2
Abstract

The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.

Claims (16)

1. An isolated anti-PcrV antibody that binds to PcrV, comprising:

a V H region that comprises a CDR3 having a sequence NRGDIYYDFTYAMDI (SEQ ID NO:99), a CDR2 sequence VISYDGSEKWYADSVKG (SEQ ID NO:57), and a CDR1 sequence NYPMH (SEQ ID NO:54); and a V L region that comprises a CDR3 having a sequence QHFWGTPYT (SEQ ID NO:110), a CDR2 sequence DASTLQS (SEQ ID NO:73) and a CDR1 sequence RASEGVDRWLA (SEQ ID NO:69).

2. The antibody of claim 1 , wherein the V H region comprises the amino acid sequence of the V-segment region of SEQ ID NO:26.

3. The antibody of claim 2 , wherein the V H region comprises the amino acid sequence set forth in SEQ ID NO:26.

4. The antibody of claim 1 , wherein the V L region comprises the amino acid sequence of the V-segment of SEQ ID NO:24.

5. The antibody of claim 4 , wherein the V L region comprises the amino acid sequence set forth in SEQ ID NO:24.

6. The antibody of claim 1 , wherein the antibody is a Fab′ fragment.

7. The antibody of claim 1 , wherein the antibody is an IgG.

8. The antibody of claim 1 , wherein the antibody is PEGylated.

9. The antibody of claim 8 , wherein the antibody is di-PEGylated.

10. The antibody of claim 1 , wherein the V H region or the V L region, or both the V H and V L region amino acid sequences comprise a methionine at the N-terminus.

11. An isolated anti-PcrV antibody that is an antagonist of the Type III secretion system, comprising: a V H region having the amino acid sequence set forth in SEQ ID NO:26 and a V L region having the amino acid sequence set forth in SEQ ID NO:24.

12. The antibody of claim 11 , wherein the V H region or the V L region, or both the V H and V L regions have a methionine present at the N-terminus.

13. The antibody of claim 11 , wherein the antibody is a di-PEGylated Fab′.

14. A composition comprising the isolated antibody of claim 11 and a pharmaceutically acceptable carrier.

15. A composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2020
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: HUMANIGEN, INC.
Reel/Frame 052920/0631 →
SECURITY INTEREST Recorded Jul 16, 2019
From: HUMANIGEN, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 049769/0067 →
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045788/0148 →
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045855/0533 →
SECURITY INTEREST Recorded Dec 22, 2016
From: KALOBIOS PHARAMECUTICALS, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 041181/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2009
From: BEBBINGTON, CHRISTOPHER R.; LUEHRSEN, KENNETH; YARRANTON, GEOFFREY T.; BAER, MARK
To: KALOBIOS PHARMACEUTICALS, INC.
Reel/Frame 022140/0868 →